Granted Patent
B2
US 12,410,403 · App. 17/200,351 · Granted Sep 9, 2025
Methods and compositions for inducing hematopoietic cell differentiation
Inventors:
Bahram Valamehr (San Diego, CA); Raedun Clarke (San Diego, CA); Ryan Bjordahl (San Diego, CA)
Assignee:
FATE THERAPEUTICS, INC.
C12N5/0647A61K35/28A61K40/10A61K40/11A61K40/31A61K40/4211G01N33/5073A61K35/545A61K2239/31A61K2239/38C12N2501/115C12N2501/125C12N2501/14C12N2501/145C12N2501/155C12N2501/165C12N2501/22C12N2501/2302C12N2501/2303C12N2501/2306C12N2501/2311C12N2501/235C12N2501/415C12N2501/727C12N2501/999C12N2506/45C12N2510/00C12N2533/90Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.
Claims (33)
1. A method of generating pluripotent stem cell derived definitive hemogenic endothelium (HE) cells, comprising culturing pluripotent stem cell derived mesodermal cells having definitive hemogenic endothelium (HE) potential in a medium comprising a GSK3 inhibitor to obtain definitive HE cells, wherein the obtained definitive HE cells:
(i) are increased in numbers and percentage in cell population;
(ii) have increased potency in differentiation; and/or
(iii) improved HE cellularity,
as compared to culturing without the GSK3 inhibitor.
2. The method of claim 1 , wherein the medium further comprises a ROCK inhibitor, and one or more growth factors and cytokines selected from the group consisting of bFGF, VEGF, SCF, IGF, EPO, IL6, and IL11.
3. The method of claim 2 , wherein the pluripotent stem cells are iPSCs.
4. The method of claim 3 , wherein the iPSCs are naïve iPSCs, and/or wherein iPSC comprises one or more genetic imprints.
5. The method of claim 4 , wherein the one or more genetic imprints comprised in the iPSC is retained in the pluripotent stem cell-derived definitive HE cells.
6. The method of claim 1 , wherein the method further comprises:
(a) isolating CD34+ cells from the cell population undergoing differentiation; or
(b) isolating CD34+CD43− cells from the cell population undergoing differentiation.
7. The method of claim 1 , wherein the pluripotent cells are iPSCs obtained by:
(a) isolating antigen-specific T cells from a selected source that is donor-, disease-, or treatment response-specific; and
(b) reprogramming the antigen-specific T cells to obtain the iPSCs.
8. The method of claim 7 , wherein isolating the antigen specific T cells further comprises enriching the antigen specific T cells by:
(a) co-culturing the antigen specific T cells with tumor cells expressing antigen(s) of interest or non-transformed cells expressing antigen(s) of interest to enable the faster proliferation of antigen-specific T cells that recognize the cell-expressed antigen of interest;
(b) co-culturing the antigen specific T cells with dendritic cells, thymic epithelial cell, endothelial cells or artificial antigen presenting cells, plasma particles or peptides expressing antigen(s) of interest; or
(c) sorting the antigen specific T cells by T cell receptor-specific binding.
9. The method of claim 7 , wherein isolating antigen specific T cells further comprises modulating, enriching and/or rejuvenating the antigen specific T cells using transcription factors or small molecules.
10. The method of claim 7 , wherein reprogramming the antigen-specific T cells to obtain the iPSCs comprises introducing one or more genetic imprints to the pluripotent stem cell by genetic editing during or after the reprogramming, wherein the genetic imprint comprises one or more genetically modified modalities obtained through genomic insertion, deletion or substitution in the genome of the iPSC.
11. The method of claim 10 , wherein the genetically modified modalities comprise one or more of: safety switch proteins, targeting modalities, receptors, signaling molecules, transcription factors, pharmaceutically active proteins and peptides, drug target candidates; cell surface proteins conveying a secondary or tertiary antigen specificity; or proteins promoting engraftment, trafficking, homing, viability, self-renewal, persistence, immune response regulation and modulation, and/or survival of the iPSCs or derivative cells thereof.
12. The method of claim 11 , wherein the genetically modified modalities comprise one or more of (i) deletion or reduced expression of B2M, TAP1, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CITTA, RFX5, or RFXAP; (ii) introduced or increased expression of HLA-E, HLA-G, HACD16, 41BBL, CD3, CD4, CD8, CD47, CD137, CD80, PDL1, A2AR, CAR, TCR, or surface triggering receptors for bi- or tri-specific engagers.
13. The method of claim 12 , wherein the surface triggering receptor is universal surface triggering receptor for the hematopoietic lineage cells comprising T, NK, NKT, macrophage, and neutrophils.
14. The method of claim 13 , wherein the universal surface triggering receptor comprises an anti-epitope and a co-stimulatory domain, wherein the anti-epitope is specific to the bi- or tri-specific engager.
15. The method of claim 14 , wherein the co-stimulatory domain comprises IL2.
16. The method of claim 14 , wherein the bi- or tri-specific engagers are specific to one or more tumor-specific antigen on the surface of a tumor cell.
17. The method of claim 16 , wherein the tumor-specific antigen comprises one or more of CD19, CD20, CD30, EGFR, HER2/ERBB2/neu, EPCAM, EphA2 and CEA.
18. The method of claim 1 , wherein the pluripotent stem cell derived mesodermal cells having definitive HE potential are obtained by:
(a) contacting iPSCs with a composition comprising a BMP pathway activator, and optionally bFGF, to obtain mesodermal cells; and
(b) contacting the mesodermal cells with a composition comprising a BMP pathway activator, bFGF, and a GSK3 inhibitor, to obtain the mesodermal cells having definitive HE potential.
19. The method of claim 18 , wherein the mesodermal cells and the mesodermal cells having definitive HE potential are obtained without forming embryoid bodies.
20. The method of claim 1 , further comprising differentiating the definitive HE cells to obtain hematopoietic stem and progenitor cells (HSC), hematopoietic multipotent progenitor cell (MPP), pre-T cell progenitor cells, pre-NK cell progenitor cells, T cell progenitor cells, NK cell progenitor cells, T cells, NK cells, NKT cells, B cells, macrophages, or neutrophils.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 16, 2021
From: VALAMEHR, BAHRAM; CLARKE, RAEDUN; BJORDAHL, RYAN
To: FATE THERAPEUTICS, INC.
Reel/Frame 055948/0921 →
Continuity (6)
Division
15773519
Continuation In Part
PCTUS2016014918
· Jan 26, 2016
Provisional Application
62337093
· May 16, 2016
Provisional Application
62251016
· Nov 4, 2015
References Cited (271)
US 5780300A
· Artavanis-Tsakonas et al.
· 1998
[cited by applicant]
US 5858358A
· June et al.
· 1999
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 5942435A
· Wheeler
· 1999
[cited by applicant]
US 6140081A
· Barbas
· 2000
[cited by applicant]
US 6352694B1
· June et al.
· 2002
[cited by applicant]
US 6453242B1
· Eisenberg et al.
· 2002
[cited by applicant]
US 6534055B1
· June et al.
· 2003
[cited by applicant]
US 6534261B1
· Cox et al.
· 2003
[cited by applicant]
US 6534476B2
· Miyazono et al.
· 2003
[cited by applicant]
US 6689744B2
· Gao et al.
· 2004
[cited by applicant]
US 6692964B1
· June et al.
· 2004
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6887466B2
· June et al.
· 2005
[cited by applicant]
US 6905680B2
· June et al.
· 2005
[cited by applicant]
US 6905681B1
· June et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7067318B2
· June et al.
· 2006
[cited by applicant]
US 7144575B2
· June et al.
· 2006
[cited by applicant]
US 7172869B2
· June et al.
· 2007
[cited by applicant]
US 7175843B2
· June et al.
· 2007
[cited by applicant]
US 7232566B2
· June et al.
· 2007
[cited by applicant]
US 7888121B2
· Urnov et al.
· 2011
[cited by applicant]
US 7972854B2
· Miller et al.
· 2011
[cited by applicant]
US 8044201B2
· Xu et al.
· 2011
[cited by applicant]
US 8168428B2
· Zon et al.
· 2012
[cited by applicant]
US 8389282B2
· Sadelain et al.
· 2013
[cited by applicant]
US 8652845B2
· Niwa et al.
· 2014
[cited by applicant]
US 9220728B2
· Sadelain et al.
· 2015
[cited by applicant]
US 9382531B2
· Slukvin et al.
· 2016
[cited by applicant]
US 9452186B2
· Shoemaker et al.
· 2016
[cited by applicant]
US 9889160B2
· Jantz et al.
· 2018
[cited by applicant]
US 20130071414A1
· Dotti et al.
· 2013
[cited by applicant]
US 20130280222A1
· Kay et al.
· 2013
[cited by applicant]
US 20170020922A1
· Wagner et al.
· 2017
[cited by applicant]
US 20180072992A1
· Valamehr et al.
· 2018
[cited by applicant]
US 20180112180A1
· Robbins et al.
· 2018
[cited by applicant]
US 20210324340A1
· Valamehr et al.
· 2021
[cited by applicant]
CN 102329769A
· 2012
[cited by applicant]
CN 102732483A
· 2012
[cited by applicant]
CN 103937743A
· 2014
[cited by applicant]
EP 1992360A1
· 2008
[cited by applicant]
EP 2606884A1
· 2013
[cited by applicant]
EP 2745840A2
· 2014
[cited by applicant]
EP 2853590A1
· 2015
[cited by applicant]
EP 2853590B1
· 2015
[cited by applicant]
JP 2011519576A
· 2011
[cited by applicant]
JP 2014501114A
· 2014
[cited by applicant]
WO WO199853058A1
· 1998
[cited by applicant]
WO WO199853059A1
· 1998
[cited by applicant]
WO WO199853060A1
· 1998
[cited by applicant]
WO WO1999001426A1
· 1999
[cited by applicant]
WO WO2002006213A2
· 2002
[cited by applicant]
WO WO2002016536A1
· 2002
[cited by applicant]
WO WO2003016496A2
· 2003
[cited by applicant]
WO WO2003077914A1
· 2003
[cited by applicant]
WO WO2005051301A2
· 2005
[cited by applicant]
WO WO2005117994A2
· 2005
[cited by applicant]
WO WO2007044084A2
· 2007
[cited by applicant]
WO WO2008006583A1
· 2008
[cited by applicant]
WO WO2008094597A2
· 2008
[cited by applicant]
WO WO2009091826A2
· 2009
[cited by applicant]
WO WO2009091826A3
· 2009
[cited by applicant]
WO WO2009091826A9
· 2009
[cited by applicant]
WO WO2009097140A1
· 2009
[cited by applicant]
WO WO2010096746A1
· 2010
[cited by applicant]
WO WO2010099539A1
· 2010
[cited by applicant]
WO WO2011096482A1
· 2011
[cited by applicant]
WO WO2011115308A1
· 2011
[cited by applicant]
WO WO2011159726A2
· 2011
[cited by applicant]
WO WO2012012667A2
· 2012
[cited by applicant]
WO WO2012021845A2
· 2012
[cited by applicant]
WO WO2012087962A2
· 2012
[cited by applicant]
WO WO2012087965A2
· 2012
[cited by applicant]
WO WO2013009825A1
· 2013
[cited by applicant]
WO WO2013074916A1
· 2013
[cited by applicant]
WO WO2013075222A1
· 2013
[cited by applicant]
WO WO2013086029A1
· 2013
[cited by applicant]
WO WO2013126794A1
· 2013
[cited by applicant]
WO WO2013158292A1
· 2013
[cited by applicant]
WO WO2013163171A1
· 2013
[cited by applicant]
WO WO2013176197A1
· 2013
[cited by applicant]
WO WO2013176916A1
· 2013
[cited by applicant]
WO WO2014011540A1
· 2014
[cited by applicant]
WO WO2014062138A1
· 2014
[cited by applicant]
WO WO2014152603A1
· 2014
[cited by applicant]
WO WO2014165131A1
· 2014
[cited by applicant]
WO WO2014165707A2
· 2014
[cited by applicant]
WO WO2014165825
· 2014
[cited by applicant]
WO WO2015164740A1
· 2015
[cited by applicant]
WO WO2016123100A1
· 2016
[cited by applicant]
WO WO2016123117A1
· 2016
[cited by applicant]
WO WO2017078807A1
· 2017
[cited by applicant]
WO WO2017079673A1
· 2017
[cited by applicant]
WO WO2017180989A2
· 2017
[cited by applicant]
Mills et al. “Hematopoietic Differentiation of Pluripotent Stem Cells in Culture” (2014), Methods in Molecular Biology 1185: Hematopoietic Stem Cell Protocols, eds. Bunting & Qu, Chapter 12: 181-194. (Year: 2014).
[cited by examiner]
Metcalfe et al. “Inhibition of GSK3 by Wnt signalling—two contrasting models” (2011) J Cell Sci, 124(21): 3537-3544. (Year: 2011).
[cited by examiner]
Wu et al. “GSK3: a mutifaceted kinase in Wnt signaling” (2009) Trends in Biochem Sci, vol. 35(3): 161-168. (Year: 2009).
[cited by examiner]
Bai et al. “The Balance of Positive and Negative Effects of TGF-beta Signaling Regulates the Devleopment of Hematopoietic and Endothelial Progenitors in Human Pluripotent Stem Cells” (2013) Stem Cells Dev, vol. 22, No. …
[cited by examiner]
Abbar et al., “Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy,”
[cited by applicant]
Ackermann et al., “Lost in translation: pluripotent stem cell-derived hematopoiesis,”
[cited by applicant]
Ahmadi et al., “CD3 limits the efficacy of TCR gene therapy in vivo,”
[cited by applicant]
Chen et al., “Development of hematopietic stem and progenitor cells from human pluripotent stem cells,”
[cited by applicant]
De Oliveira et al., “Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy,”
[cited by applicant]
Ditadi et al., “Directed differentiation of definitive hemogenic endothelium and hematopoietic progenitors from human pluripotent stem cells,”
[cited by applicant]
Gori et al., “Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells,”
[cited by applicant]
Hao et al., “Recent progress on chemical biology of pluripotent stem cell self-renewal, reprogramming and cardiomyogenesis,” Recent Pat. Regen. Med., 1(3):263-274 (2011).
[cited by applicant]
Jehuda et al., “Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9,”
[cited by applicant]
Kim et al., “Genomic editing tools to model human diseases with isogenic pluripotent stem cells,”
[cited by applicant]
Lee et al., “Inhibition of pluripotent stem cell-derived teratoma formation by small molecules,”
[cited by applicant]
Lei et al., “Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes,”
[cited by applicant]
Loh et al., “Reprogramming of T cells from human peripheral blood,”
[cited by applicant]
Maeder et al., “Genome-editing Technologies for Gene and Cell Therapy,” Mol. Ther., 24(3):430-446 (2016).
[cited by applicant]
Mali et al., “RNA-guided human genome engineering via Cas9,”
[cited by applicant]
NIH Stem Cell Information, “Stem Cell Basics,” Retrieved from the Internet: https://stemcells.nih.gov/info/basics/stc-basics/#stc-II [retrieved on Sep. 29, 2021].
[cited by applicant]
Osborn et al., “Evaluation of TCR Gene Editing Achieved by TALENS, CRISPR/Cas9, and megaTAL Nucleases,”
[cited by applicant]
Sato et al., “Establishment of β-2 microglobulin deficient human iPS cells using CRISPR/Cas9 system,”
[cited by applicant]
Schiroli et al., “Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1,” Sci. Transl. Med., 9(411):1-11 (2017).
[cited by applicant]
Vocabulary.com printout, pp. 1-2, printed 2023.
[cited by applicant]
Yagyu et al., “An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells,”
[cited by applicant]
Ying et al., “The ground state of embryonic step cell self-renewal,”
[cited by applicant]
Ameri et al., “FGF2 specifies hESC-derived definitive endoderm into foregut/midgut cell lineages in a concentration-dependent manner,”
[cited by applicant]
Ansari et al., “The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice,”
[cited by applicant]
Beilhack et al., “Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice,”
[cited by applicant]
Birch et al., “Suspension culture of mammalian cells,” Bioprocess Technol., 10:251-270 (1990).
[cited by applicant]
Brentjens et al., “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts,” Clin. Cancer Res., 13(18Pt 1):5426-5435 (2007).
[cited by applicant]
Brentjens et al., “Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial,” Mol. Ther., 18(4):666-668 (2010).
[cited by applicant]
Brevini et al., “No shortcuts to pig embryonic stem cells,”
[cited by applicant]
Brown et al., “Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes,” PLoSOne, 5(6):e11373 (2010).
[cited by applicant]
Bykovskaia, S.N. et al. (Oct. 1999). “The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin-15,” J Leukoc Biol 66(4):659-666.
[cited by applicant]
Chang et al., “Transforming growth factor-beta signaling in breast cancer”, Frontiers in Bioscience, 12: 4393-4401 (2007).
[cited by applicant]
Chen, W. et al. (Jun. 2014). “Generation of the SCN1A epilepsy mutation in hiPS cells using the TALEN technique,” Scientific Reports 4:5404, pp. 1-7.
[cited by applicant]
Chiang et al., “Differentiation of an embryonic stem cell to hemogenic endothelium by defined factors: essential role of bone morphogenetic protein 4,” Development, 138(13):2833-2843 (2011).
[cited by applicant]
Choi et al., “Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures,” Cell Rep., 2(3):553-567 (2012).
[cited by applicant]
Cui et al., “Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP”, Oncogene, 24: 3864-3874 (2005).
[cited by applicant]
Dacosta et al., “SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7,” Mol. Pharmacol., 65(3):744-752 (2004).
[cited by applicant]
D'Addio et al., “Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis,” Diabetes, 63:3041-3046 (2014).
[cited by applicant]
De Gouville and Huet, “Inhibition of ALK5 as a new approach to treat liver fibrotic diseases”, Drug News Perspective, 19(2): 85-90 (2006).
[cited by applicant]
Dravid, G. (Nov.-Dec. 2005, e-published Jul. 7, 2005). “Defining the role of Wnt/β-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells,” Stem Cells 23(10):1489-1501.
[cited by applicant]
Ducy, P. et al. (Jun. 2000). “The family of bone morphogenetic proteins,” Kidney Int 57(6):2207-2214.
[cited by applicant]
Eiselleova et al., “A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells,”
[cited by applicant]
Eyquem, J. et al. (Mar. 2, 2017, e-published Feb. 22, 2017). “Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection,” Nature 543(7643): 113-117.
[cited by applicant]
Figueiredo et al., “Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery,” J. Mol. Med., 84(5):425-437 (2006).
[cited by applicant]
Fiorina et al., “Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1,”
[cited by applicant]
French et al., “Human induced pluripotent stem cell-derived B lymphocytes express slgM and can be generated via a hemogenic endothelium intermediate,” Stem Cells and Development, 24(9):1082-1095 (2015).
[cited by applicant]
Gellibert et al., “Discovery of 4-{4-[3-(Pyridin-2-y1)-1H-pyrazol-4-yl]pyridin-2-y1}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor …
[cited by applicant]
Gong et al., “Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen,” Neoplasia…
[cited by applicant]
Hoffman, L.M. et al. (Jun. 2005). “Characterization and culture of human embryonic stem cells,” Nat Biotechnol 23(6):699-708.
[cited by applicant]
Hoggatt et al., “Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation,”
[cited by applicant]
Hu et al., “Large-scale mammalian cell culture,” Curr. Opin. Biotechnol., 8(2):148-153 (1997).
[cited by applicant]
Huang et al., “Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice,” J. Clin. Invest., 119(12):3519-3529 (2009).
[cited by applicant]
Inman et al., “SB-431542 is a potent and specific inhibitor of transforming growth factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7”, Molecular Pharmacology, 62(1): 65-74 (20…
[cited by applicant]
Joo et al., “ROCK suppression promotes differentiation and expansion of endothelial cells from embryonic stem cell-derived Flk1(+) mesodermal precursor cells,” Blood, 120(13):2733-2744 (2012).
[cited by applicant]
Kaminska, et al., “TGF beta signalling and its role in tumour pathogenesis”, Acta Biochimica Polonica, 52(2): 329-337 (2005).
[cited by applicant]
Kennedy et al., “T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures,” Cell Rep., 2(6):1722-1735 (2012).
[cited by applicant]
Kim, et al., “Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-y1)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug”, Xenobiotica, 38(3…
[cited by applicant]
Kitano, “Serum-free media,” in Animal Cell Bioreactors, eds. Ho and Wang, Butterworth-Heinemann, Stoneham, MA, Chapter 4, pp. 73-106 (1991).
[cited by applicant]
Knorr et al., “Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy,” Stem Cells Transl. Med., 2(4):274-283 (2013).
[cited by applicant]
Knorr et al., “Engineering Human Pluripotent Stem Cells for Enhanced Lymphocyte Development and Function a Dissertation Submitted to the Faculty of the Graduate School of the University of Minnesota By,” Oct. 2012, Retr…
[cited by applicant]
Knorr et al., “Pluripotent stem cell-derived natural killer cells for cancer therapy,” Transl. Res., 156(3):147-154 (2010).
[cited by applicant]
Krawetz et al., “Inhibition of Rho kinase regulates specification of early differentiation events in P19 embryonal carcinoma stem cell, ” PLoS One, 6(11):e26484 (2011).
[cited by applicant]
Kumar, D. et al. (Mar. 26, 2015,). “Induced Pluripotent Stem Cells: Mechanisms, Achievements and Perspectives in Farm Animals,” World J Stem Cells 7(2):315-328.
[cited by applicant]
Li, W. et al. (Dec. 2009). “Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2,” Stem Cells 27(12):2992-3000.
[cited by applicant]
Lian et al., “Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling,” Stem Cell Reports, 3(5):804-816 (2014).
[cited by applicant]
Lu, Y. et al. (Aug. 2012). “Livestock Induced Pluripotent Stem Cells,” Reprod Domest Anim 47(Suppl 4):72-76.
[cited by applicant]
Macleod, D.T. et al. (Apr. 5, 2017, e-published Feb. 23, 2017). “Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells,” Mol Ther 25(4):949-961.
[cited by applicant]
Maher et al., “Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor,” Nat. Biotechnol., 20(1):70-75 (2002).
[cited by applicant]
Meijer, L. et al. (Sep. 2004). “Pharmacological inhibitors of glycogen synthase kinase 3,” Trends Pharmacol Sci 25(9):471-480.
[cited by applicant]
Menon et al., “Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs,”
[cited by applicant]
Mikels, A.J. et al. (Dec. 4, 2006). “Wnts as ligands: processing, secretion and reception,” Oncogene 25(57):7461-7468.
[cited by applicant]
Munoz et al., “Constraints to progress in embryonic stem cells from domestic species,” Stem Cell Rev. Rep., 5:6-9 (2009).
[cited by applicant]
Munoz et al., “Conventional pluripotency markers are unspecific for bovine embryonic-derived cell-lines,”
[cited by applicant]
Nazareth, E.J. et al. (Dec. 2010, e-published Oct. 20, 2013). “High-throughput fingerprinting of human pluripotent stem cell fate responses and lineage bias,” Nat Methods 10(12):1225-1231.
[cited by applicant]
Ninomiya, H. et al. (Jan. 2015, e-published Aug. 15, 2014). “Improved efficiency of definitive endoderm induction from human induced pluripotent stem cells in feeder and serum-free culture system,” In Vitro Cell Dev Bio…
[cited by applicant]
Nishimura et al., “Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation,” Cell Stem Cell, 12(1):114-126 (2013).
[cited by applicant]
Ogorevc, J. et al. (Feb. 19, 2016). “Cellular reprogramming in farm animals: an overview of iPSC generation in the mammalian farm animal species,” J Anim Sci Biotechnol 7:10.
[cited by applicant]
Ozkaynak et al., “Programmed death-1 targeting can promote allograft survival,”
[cited by applicant]
Papapetrou et al., “Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells,” Nat. Biotechnol., 29(1):73-78 (2011).
[cited by applicant]
Paris et al., “Equine embryos and embryonic stem cells: defining reliable markers of pluripotency,”
[cited by applicant]
Paterson, Y.Z. et al. (Jan. 2018, e-published Jul. 5, 2017). “Characterization of companion animal pluripotent stem cells,” Cytometry A 93(1):137-148.
[cited by applicant]
Pearson et al., “The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF,” Development, 135:1525-1535 (2008).
[cited by applicant]
Poirot et al., “Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies,” Cancer Res., 75(18):3853-3864 (2015).
[cited by applicant]
Rahman et al., “Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model,”
[cited by applicant]
Rathjen et al., “Properties and uses of embryonic stem cells: prospects for application to human biology and gene therapy,” Reprod. Fertil. Dev., 10:31-47 (1998).
[cited by applicant]
Riella et al., “Role of the PD-1 pathway in the immune response,”
[cited by applicant]
Robertston, “Derivation and maintenance of embryonic stem cell cultures,” Methods Mol. Biol., 75:173-184 (1997).
[cited by applicant]
Sadelain et al., “The promise and potential pitfalls of chimeric antigen receptors,” Curr. Opin. Immunol.21(2):215-223 (2009).
[cited by applicant]
Sato, T. et al. (Nov. 2007). “High-level expression of CD109 is frequently detected in lung squamous cell carcinomas,” Pathology International 57(11):719-724.
[cited by applicant]
Schmitt et al., “Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro,” Nat. Immunol., 5(4):410-417 (2004).
[cited by applicant]
Schmitt et al., “Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro,” Immunity, 17(6):749-756 (2002).
[cited by applicant]
Shimanuki et al., “Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling”, Oncogene, 26: 3311-3320 (2007).
[cited by applicant]
Shimasaki, S. et al. (Feb. 2004). “The bone morphogenetic protein system in mammalian reproduction,” Endocr Rev 25(1):72-101.
[cited by applicant]
Smith, C. et al. (Mar. 2015, e-published Nov. 24, 2014). “Efficient and allele-specific genome editing of disease loci in human iPSCs,” Mol Ther 23(3):570-577.
[cited by applicant]
Song et al., “Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system,”
[cited by applicant]
Spier, “Large-scale mammalian cell culture: methods, applications and products,” Curr. Opin. Biotechnol. 2(3):375-379 (1991).
[cited by applicant]
Suzuki et al., “A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection”…
[cited by applicant]
Themeli, M. et al. (Oct. 2013, e-published Aug. 11, 2013). “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nat Biotechnol 31(10):928-933.
[cited by applicant]
Themeli, M. et al. (Apr. 2, 2015). “New cell sources for T cell engineering and adoptive immunotherapy,” Cell Stem Cell 16(4):357-366.
[cited by applicant]
Tojo, et al., “The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelia-to-mesenchymal transition by transforming growth factor-β,” Cancer Sci, 96(11): 791-800 (2005).
[cited by applicant]
Torikai et al., “A foundation for universal T-cell based immunotherapy: T cell engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR,” Blood, 119(24):5697-5705 (2012).
[cited by applicant]
Tsutsui, H. et al. (Jan. 2011). “An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells,” Nat Commun 2:167.
[cited by applicant]
Valamehr, B. et al. (Sep. 2011). “Developing defined culture systems for human pluripotent stem cells,” Regen Med 6(5):623-634.
[cited by applicant]
Valamehr et al., “A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs,” Sci. Rep., 2:213:1-11 (2012).
[cited by applicant]
Valamehr et al., “Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells,” Stem Cell Reports, 2:366-381 (2014).
[cited by applicant]
Verfaillie, C.M. et al. (2002). “Stem cells: hype and reality,” Hematology Am Soc Hematol Educ Program 369-391.
[cited by applicant]
Vijayaragavan et al., “Noncanonical Wnt signaling orchestrates early developmental events toward hematopoietic cell fate from human embryonic stem cells,” Cell Stem Cell, 4:248-262 (2009).
[cited by applicant]
Vizcardo, R. et al. (Jan. 3, 2013). “Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells,” Cell Stem Cell 12(1):31-36.
[cited by applicant]
Vodyanik et al., “Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures,”
[cited by applicant]
Voltarelli et al., “Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus,”
[cited by applicant]
Wang et al., “WNT and BMP signaling are both required for hematopoietic cell development from human ES cells,” Stem Cell Res., 3(2-3):113-125 (2009).
[cited by applicant]
Wiles, “Embryonic stem cell differentiation in vitro,” Methods Enzymol., 225:900-918 (1993).
[cited by applicant]
Wrzesinski, et al., “Transforming growth factor-beta and the immune response: implications for anticancer therapy”, Clinical Cancer Research, 13(18): 5262-5270 (2007).
[cited by applicant]
Xu et al., “BMP4 initiates human embryonic stem cell differentiation to trophoblast,”
[cited by applicant]
Yamane et al., “Expression of AA4.1 marks lymphohematopoietic progenitors in early mouse development,” Proc. Natl. Acad. Sci. USA, 106(22):8953-8958 (2009).
[cited by applicant]
Zhao et al., “Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA”, Molecular Biology of the Cell, 17(9): 3819-3831 (200…
[cited by applicant]
Zheng et al., “Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation,” Cell Stem Cell, 9:119-130 (2011).
[cited by applicant]
Ditadi et al.,“Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages,”
[cited by applicant]
Engle et al., “Integrating human pluripotent stem cells into drug development,”
[cited by applicant]
Feng et al., “Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells,”
[cited by applicant]
Hayashi et al., “Pluripotent Stem Cell Heterogeneity,” Stem Cells Heterogeneity—Novel Concepts,
[cited by applicant]
Slukvin et al., “Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells,”
[cited by applicant]
Van Der Stegen et al., “NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells,”
[cited by applicant]